Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer

OnKure Therapeutics, Inc.

Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.
Cruse granted option for 25,000 shares vesting in 48 equal monthly installments; severance extended to 12 months post-change-of-control.
Jennifer P. Lam named principal financial and accounting officer effective March 31, 2022; base salary raised to $320K (from $309K).
Lam granted option for 10,000 shares vesting over 48 months; she previously served as VP of Finance & Administration since August 2021.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer P. Lam

principal financial and accounting officer

OKUR · OnKure Therapeutics, Inc.

Effective: 2022-03-31
Filed: March 7, 2022, 6:59 PM ET

On March 2, 2022, the Board appointed Jennifer P. Lam, the Company’s Vice President of Finance & Administration, as the Company’s principal financial and accounting officer, effective March 31, 2022 (the “Lam Appointment”).

Appointed

Michael P. Cruse

Chief Operating Officer

OKUR · OnKure Therapeutics, Inc.

Effective: 2022-03-02
Filed: March 7, 2022, 6:59 PM ET

On March 2, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”) appointed Michael P. Cruse as the Company’s Chief Operating Officer, effective immediately (the “Cruse Appointment”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer P. Lam was appointed as principal financial and accounting officer at OnKure Therapeutics, Inc..

Action: appointed
Role: principal financial and accounting officer

Exact text from the filing

On March 2, 2022, the Board appointed Jennifer P. Lam, the Company’s Vice President of Finance & Administration, as the Company’s principal financial and accounting officer, effective March 31, 2022 (the “Lam Appointment”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael P. Cruse was appointed as Chief Operating Officer at OnKure Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On March 2, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”) appointed Michael P. Cruse as the Company’s Chief Operating Officer, effective immediately (the “Cruse Appointment”).

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-068011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.